Administration of the hypoxia-inducible factor–2α inhibitor belzutifan (Welireg) at the recommended phase 2 dose of 120 mg daily produced comparable toxicities and efficacy outcomes to that of a daily 200-mg dose of the agent in patients with advanced clear cell renal cell carcinoma.
Yousef Zakharia, MD, discusses the real-world treatment outcomes of first-line axitinib plus pembrolizumab in patients with advanced renal cell carcinoma based on International Metastatic RCC Database Consortium risk score.
Treatment with zanzalintinib monotherapy produced antitumor activity and was well tolerated in patients with previously treated advanced clear cell renal cell carcinoma.
Jaleh Fallah, MD, discusses the FDA's evaluation of data from the phase 2 LITESPARK-004 trial, which supported the approval of belzutifan in von Hippel-Lindau–associated cancers.
Sumanta Kumar Pal, MD, FASCO, discusses outcomes with the use of zanzalintinib in patients with relapsed/refractory clear cell renal cell carcinoma.
Improvements in screening, systemic therapy, and precision medicine have reduced breast cancer mortality and morbidity, and further progress will hinge on the use of ctDNA and CTCs for disease monitoring, continued development of novel antiestrogenic agents, and movement of ADCs and immunotherapy into expanded settings and indications.
Howard I. Scher, MD, discusses the evolution of molecular testing mechanisms in patients with prostate cancer and highlights the importance of making patient-centered decisions based on test results.
Howard I. Scher, MD, sheds light on various research programs he has led or has been heavily involved with that have helped change the course of prostate cancer treatment over the years.
Komal Jhaveri , MD, FACP, discusses the rationale behind the ongoing clinical development of elacestrant and other endocrine therapies in patients with estrogen receptor–positive metastatic breast cancer.
The combination of enfortumab vedotin-ejfv plus pembrolizumab represents a chemotherapy-free regimen that could alter the standard of care in the frontline treatment of all patients with metastatic urothelial carcinoma.
David Braun, MD, PhD, discusses the findings from the phase 3 CONTACT-03 trial investigating immunotherapy rechallenge in patients with renal cell carcinoma and the implications of these findings on the RCC treatment paradigm.
Immune checkpoint inhibitors have been associated with improved outcomes for patients with metastatic translocation renal cell carcinoma; however, novel therapies and therapeutic targets are needed for patients within this histologic subset.
Douglas A. Tremblay, MD, discusses the prevalence of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes and the evolving treatment paradigm for these diseases.
Research has continued to focus on developing novel therapies and bringing new treatments to the sarcoma treatment paradigm.
The mitigation and management of toxicities is a key component of treating patients with biliary tract cancers with targeted therapies.
Marc J. Braunstein, MD, PhD, discusses the evolution of stem cell transplant eligibility criteria in patients with multiple myeloma and highlights unanswered questions about the role of autologous stem cell transplantation following quadruplet induction regimens in this population.
Maurie Markman, MD, discusses the importance of designing clinical trials for patients with ovarian cancer that are based on real-world data and consider the increasing complexity of treatment sequencing in this disease.
Although advancements were “simple” to track for more than 40 years and left few questions open for evaluation in the ovarian cancer treatment paradigm, new questions have begun to develop surrounding the complexity of care.
Gilles Salles, MD, PhD, expands on how data from recent clinical trials have helped shift the treatment paradigm for patients with diffuse large B-cell lymphoma.
Nicole Lamanna, MD, discusses treatment options for patients with chronic lymphocytic leukemia who develop resistance to a prior treatment.
Along with the combination of venetoclax and obinutuzumab, the BTK inhibitor–based regimens of zanubrutinib monotherapy and acalabrutinib plus obinutuzumab represent the preferred options in the National Comprehensive Cancer Network Guidelines for the first-line treatment of patients with chronic lymphocytic leukemia without 17p deletions or TP53 mutations.
R. Jonathan Henderson, MD, discusses incorporating immunotherapy agents into practice in patients with bladder cancer.
Benjamin H. Lowentritt, MD, FACS, discusses the exploration of active surveillance in patients with prostate cancer.
David Morris, MD, FACS, discusses the best practices for active surveillance in low- and intermediate-risk patients with prostate cancer, highlighting factors to look for in patients undergoing active surveillance that may point to the need for further treatment.
E. David Crawford, MD, discusses the evolving role of active surveillance in patients with prostate cancer.
Improved toxicity, advanced technology, and novel techniques have helped increase the use of radiotherapy for the treatment of different subgroups of patients with prostate cancer.
Active surveillance can provide eligible patients with low-risk prostate cancer the opportunity to defer or avoid treatment and instead opt for routine monitoring of their disease; however, challenges arise when determining which patients should be eligible for this approach and how to maintain patient and provider protocol compliance.
David Morris, MD, FACS, discusses the increasing the use of active surveillance in patients with low-risk prostate cancer and the goals of avoiding adverse effects associated with possible therapies.
Gautam Jayram, MD, discusses the current indications for immunotherapy agents in the bladder cancer treatment paradigm, as well as immune-related adverse effects to be aware of when treating patients who are receiving these therapies.
Gautam Jayram, MD, discusses current standards of care in the bladder cancer treatment arena, novel therapies under investigation in clinical trials that may expand the arsenal of available treatment strategies, and emphasizes the importance of implementing bladder cancer programs.
